Peng C, Wang W, Chen J, Pan S, Xu G, Li M
J Int Med Res. 2024; 52(12):3000605241304640.
PMID: 39719073
PMC: 11694285.
DOI: 10.1177/03000605241304640.
Chatzkel J, Fishman M, Ramnaraign B, OMalley P, Sonpavde G
Res Rep Urol. 2024; 16:161-176.
PMID: 39072353
PMC: 11282163.
DOI: 10.2147/RRU.S457287.
Lama D, Thomas K, Vernez S, Okunowo O, Lau C, Yuh B
BMC Urol. 2024; 24(1):72.
PMID: 38532371
PMC: 10964602.
DOI: 10.1186/s12894-024-01463-2.
Iisager L, Ahrenfeldt J, Donskov F, Ljungberg B, Bex A, Lund L
BMC Cancer. 2024; 24(1):260.
PMID: 38402173
PMC: 10893632.
DOI: 10.1186/s12885-024-11987-3.
Reese S, Eismann L, White C, Villada J, Khaleel S, Ostrovnaya I
Urol Oncol. 2023; 42(2):32.e9-32.e16.
PMID: 38135627
PMC: 10922785.
DOI: 10.1016/j.urolonc.2023.12.003.
Image-Guided Ablations in Patients with Recurrent Renal Cell Carcinoma.
Aurilio G, Mauri G, Rossi D, Della Vigna P, Bonomo G, Varano G
J Clin Med. 2023; 12(15).
PMID: 37568303
PMC: 10420241.
DOI: 10.3390/jcm12154902.
Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC.
Das A, Shapiro D, Craig J, Abel E
Nat Rev Urol. 2023; 20(11):654-668.
PMID: 37400492
DOI: 10.1038/s41585-023-00776-5.
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Santoni M, Massari F, Myint Z, Iacovelli R, Pichler M, Basso U
Target Oncol. 2023; 18(4):559-570.
PMID: 37369815
DOI: 10.1007/s11523-023-00978-2.
Do patients with metastatic renal cell carcinoma obtain survival benefits from cytoreductive nephrectomy? A population-based study.
Luo Z, Jiao B, Xu Q, He W, Zhao H, Liu Y
J Cancer Res Clin Oncol. 2023; 149(12):9657-9670.
PMID: 37231275
DOI: 10.1007/s00432-023-04885-x.
Prognostic Factors for Survival in Patients Undergoing Surveillance After Cytoreductive Nephrectomy.
Reese S, Khaleel S, Silagy A, Xie A, Eismann L, Vazquez-Rivera K
J Urol. 2023; 210(2):273-279.
PMID: 37167628
PMC: 10726735.
DOI: 10.1097/JU.0000000000003549.
Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.
Napolitano L, Manfredi C, Cirillo L, Fusco G, Passaro F, Abate M
Medicina (Kaunas). 2023; 59(4).
PMID: 37109725
PMC: 10143323.
DOI: 10.3390/medicina59040767.
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.
Hahn A, Kotecha R, Viscuse P, Pieretti A, Wiele A, Jonasch E
Eur Urol Focus. 2023; 9(5):734-741.
PMID: 36863962
PMC: 10460829.
DOI: 10.1016/j.euf.2023.02.008.
Machine learning to improve prognosis prediction of metastatic clear-cell renal cell carcinoma treated with cytoreductive nephrectomy and systemic therapy.
Yang W, Ma L, Dong J, Wei M, Ji R, Chen H
Biomol Biomed. 2022; 23(3):471-482.
PMID: 36326180
PMC: 10171449.
DOI: 10.17305/bjbms.2022.8047.
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.
Rebuzzi S, Signori A, Banna G, Gandini A, Fornarini G, Damassi A
J Transl Med. 2022; 20(1):435.
PMID: 36180954
PMC: 9524042.
DOI: 10.1186/s12967-022-03601-6.
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma.
Ingels A, Campi R, Capitanio U, Amparore D, Bertolo R, Carbonara U
Nat Rev Urol. 2022; 19(7):391-418.
PMID: 35546184
DOI: 10.1038/s41585-022-00592-3.
Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents.
Teishima J, Goto K, Sekino Y, Mita K, Hayashi T, Hasegawa Y
Int Urol Nephrol. 2022; 54(6):1225-1232.
PMID: 35314918
DOI: 10.1007/s11255-022-03157-w.
Re: Comparison of immediate deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial.
Minervini A, Mari A, Di Maida F, Campi R, Carini M, Lapini A
Transl Cancer Res. 2022; 8(Suppl 2):S208-S210.
PMID: 35117099
PMC: 8797348.
DOI: 10.21037/tcr.2019.03.08.
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Motzer R, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K
J Natl Compr Canc Netw. 2022; 20(1):71-90.
PMID: 34991070
PMC: 10191161.
DOI: 10.6004/jnccn.2022.0001.
Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study.
Kato R, Naito S, Numakura K, Hatakeyama S, Koguchi T, Kojima T
Int J Clin Oncol. 2022; 27(3):563-573.
PMID: 34973106
PMC: 8882566.
DOI: 10.1007/s10147-021-02091-8.
Oligometastatic prostate cancer: definition and the role of local and systemic therapy: a narrative review.
Mahjoub S, Heidenreich A
Transl Androl Urol. 2021; 10(7):3167-3175.
PMID: 34430419
PMC: 8350250.
DOI: 10.21037/tau-20-1033.
